NO20021821L - Natrium-hydrogen utvekslingstype 1 inhibitor krystaller - Google Patents

Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Info

Publication number
NO20021821L
NO20021821L NO20021821A NO20021821A NO20021821L NO 20021821 L NO20021821 L NO 20021821L NO 20021821 A NO20021821 A NO 20021821A NO 20021821 A NO20021821 A NO 20021821A NO 20021821 L NO20021821 L NO 20021821L
Authority
NO
Norway
Prior art keywords
sodium
inhibitor crystals
exchange type
hydrogen exchange
crystals
Prior art date
Application number
NO20021821A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021821D0 (no
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20021821D0 publication Critical patent/NO20021821D0/no
Publication of NO20021821L publication Critical patent/NO20021821L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021821A 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller NO20021821L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (fr) 1999-10-29 2000-10-09 Cristaux d'inhibiteurs de l'echangeur sodium-hydrogene de type 1

Publications (2)

Publication Number Publication Date
NO20021821D0 NO20021821D0 (no) 2002-04-18
NO20021821L true NO20021821L (no) 2002-04-18

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021821A NO20021821L (no) 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Country Status (44)

Country Link
EP (1) EP1224179B1 (fr)
JP (1) JP2003512455A (fr)
KR (1) KR100464526B1 (fr)
CN (2) CN1205205C (fr)
AP (1) AP2002002493A0 (fr)
AR (1) AR029402A1 (fr)
AT (1) ATE271047T1 (fr)
AU (1) AU778573B2 (fr)
BG (1) BG106729A (fr)
BR (1) BR0015275A (fr)
CA (1) CA2389020A1 (fr)
CO (1) CO5271714A1 (fr)
CZ (1) CZ20021332A3 (fr)
DE (1) DE60012208T2 (fr)
DK (1) DK1224179T3 (fr)
DZ (1) DZ3463A1 (fr)
EA (1) EA004937B1 (fr)
EE (1) EE200200227A (fr)
ES (1) ES2222923T3 (fr)
GE (1) GEP20043222B (fr)
GT (1) GT200000180A (fr)
HK (1) HK1048472B (fr)
HR (1) HRP20020366B1 (fr)
HU (1) HUP0204009A3 (fr)
IL (1) IL148581A0 (fr)
IS (1) IS6302A (fr)
MA (1) MA26840A1 (fr)
MX (1) MXPA02004358A (fr)
NO (1) NO20021821L (fr)
NZ (1) NZ517738A (fr)
OA (1) OA12080A (fr)
PA (1) PA8505501A1 (fr)
PE (1) PE20010764A1 (fr)
PL (1) PL354869A1 (fr)
PT (1) PT1224179E (fr)
SI (1) SI1224179T1 (fr)
SK (1) SK5312002A3 (fr)
SV (1) SV2002000209A (fr)
TN (1) TNSN00210A1 (fr)
TR (1) TR200201167T2 (fr)
UA (1) UA72002C2 (fr)
WO (1) WO2001030759A2 (fr)
YU (1) YU31502A (fr)
ZA (1) ZA200203295B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
CN1479737A (zh) * 2001-01-31 2004-03-03 �Ʒ� 钠-质子交换蛋白1型抑制剂的乙醇盐
BR0307195A (pt) * 2002-01-30 2004-11-03 Pfizer Prod Inc Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1056729E (pt) * 1998-02-27 2005-04-29 Pfizer Prod Inc Derivados de n-[ciclo di- ou tri-aza di-insaturado de cinco membros substituido) carbonil] guanidina para o tratamento de isquemia

Also Published As

Publication number Publication date
DE60012208D1 (de) 2004-08-19
CA2389020A1 (fr) 2001-05-03
HRP20020366B1 (en) 2005-04-30
AP2002002493A0 (en) 2002-06-30
NO20021821D0 (no) 2002-04-18
ZA200203295B (en) 2003-06-25
DZ3463A1 (fr) 2001-05-03
BR0015275A (pt) 2002-07-16
PL354869A1 (en) 2004-03-08
HK1048472B (zh) 2005-09-16
NZ517738A (en) 2005-06-24
ES2222923T3 (es) 2005-02-16
IL148581A0 (en) 2002-09-12
BG106729A (bg) 2002-12-29
IS6302A (is) 2002-03-15
OA12080A (en) 2003-08-25
CZ20021332A3 (cs) 2002-10-16
HUP0204009A2 (hu) 2003-03-28
CN1384829A (zh) 2002-12-11
KR20020040918A (ko) 2002-05-30
EA004937B1 (ru) 2004-10-28
EP1224179B1 (fr) 2004-07-14
TNSN00210A1 (fr) 2005-11-10
GT200000180A (es) 2002-04-11
EP1224179A2 (fr) 2002-07-24
HUP0204009A3 (en) 2004-07-28
CO5271714A1 (es) 2003-04-30
HK1048472A1 (en) 2003-04-04
SV2002000209A (es) 2002-07-16
YU31502A (sh) 2004-12-31
PE20010764A1 (es) 2001-07-23
AU7441500A (en) 2001-05-08
GEP20043222B (en) 2004-04-26
ATE271047T1 (de) 2004-07-15
DK1224179T3 (da) 2004-10-25
AU778573B2 (en) 2004-12-09
JP2003512455A (ja) 2003-04-02
EA200200416A1 (ru) 2002-10-31
CN1636991A (zh) 2005-07-13
UA72002C2 (en) 2005-01-17
CN1205205C (zh) 2005-06-08
KR100464526B1 (ko) 2005-01-03
AR029402A1 (es) 2003-06-25
MA26840A1 (fr) 2004-12-20
DE60012208T2 (de) 2005-07-21
SK5312002A3 (en) 2003-01-09
EE200200227A (et) 2003-06-16
PA8505501A1 (es) 2003-09-05
HRP20020366A2 (en) 2004-02-29
WO2001030759A2 (fr) 2001-05-03
WO2001030759A3 (fr) 2001-09-13
MXPA02004358A (es) 2002-11-07
SI1224179T1 (en) 2004-10-31
TR200201167T2 (tr) 2002-08-21
PT1224179E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
NO20006323L (no) Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO20011023D0 (no) Arylpiperaziner og anvendelse derav som metalloproteinase inhiberende midler (MMP)
AP2002002458A0 (en) Compounds for the treatment of ischemia.
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
AR024138A1 (es) Inhibidores de la proliferacion celular
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
NO944406L (no) Nye 7 e inhibitorer
NO980178L (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
DE60117594D1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BG104575A (en) Matrix metalloprotease inhibitors
ATE229800T1 (de) Guanidino proteiase inhibitoren
NO20021821L (no) Natrium-hydrogen utvekslingstype 1 inhibitor krystaller
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
AP2002002651A0 (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
DK1017681T3 (da) Hydrazon-benzazulenderivater, farmaceutiske præparater og mellemprodukter
MXPA04004685A (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
YU62900A (sh) Postupak za dobijanje inhibitora za tip 1 izmenjivača natrijum-vodonik
DK0971714T3 (da) Metode til anvendelse af cyklooxygenase-2-inhibitorer til behandling og forebyggelse af demens
UY26417A1 (es) Cristales de inhibidor del intercambiador de sodio-hidrógeno tipo 1
ECSP982785A (es) Nuevos compuestos de tetrahidroizoquinoleinil- carboxamida, de formula (i) y procedimiento para su obtencion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application